Evercore ISI upgraded Novocure (NVCR) to Outperform from In Line with a $30 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure announces FDA approval of new head flexible electrode transducer arrays
- Novocure participates in a conference call with JPMorgan
- Novocure’s Q3 2024 Results Highlight Growth and Innovation
- NovoCure’s Strong Q3 and Leadership Changes in 2024
- Novocure appoints Christoph Brackmann as Chief Financial Officer